Altered gene expression and PTSD symptom dimensions in World Trade Center responders

- 3 Shelby Marchese¹, Leo Cancelmo², Olivia Diab², Leah Cahn², Cindy Aaronson², Nikolaos P.
- 4 Daskalakis^{2,3}, Jamie Schaffer², Sarah R Horn², Jessica S. Johnson¹, Clyde Schechter⁴, Frank Desarnaud^{2,5},
- 5 Linda M Bierer^{2,5}, Iouri Makotkine^{2,5}, Janine D Flory^{2,5}, Michael Crane⁶, Jacqueline M. Moline⁷, Iris
- 6 G. Udasin⁸, Denise J. Harrison⁹, Panos Roussos^{1,2,10-12}, Dennis S. Charnev^{2,13,14}, Karestan C Koenen¹⁵⁻
- 7 ¹⁷, Steven M. Southwick¹⁸⁻¹⁹, Rachel Yehuda^{2,5}, Robert H. Pietrzak¹⁸⁻¹⁹, Laura M. Huckins^{1,2,10}-
- 8 12,20*, Adriana Feder²* (* equal contribution)
- 10 Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York,
- 11 NY 10029, USA

1

2

9

- ² Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- ³ Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA
- ⁴ Department of Family and Social Medicine, Albert Einstein College of Medicine of Yeshiva
- 15 University, Bronx, NY, USA
- ⁵ Department of Psychiatry, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA
- 17 ⁶ Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai,
- 18 New York, NY, USA
- 19 ⁷ Department of Occupational Medicine, Epidemiology and Prevention, Zucker School of Medicine at
- Hofstra/Northwell, Great Neck, NY, USA
- 21 ⁸ Environmental and Occupational Health Sciences Institute, School of Public Health, Rutgers
- 22 University, Piscataway, NJ, USA
- ⁹ Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, NYU School of
- Medicine, New York, NY, USA
- 25 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,
- 26 NY 10029, USA

¹¹ Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New 27 28 York, NY 10029, USA ¹² Mental Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans 29 30 Affairs Medical Center, Bronx, NY 14068, USA ¹³ Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 31 ¹⁴ Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New 32 33 York, USA. ¹⁵ Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston, 34 35 MA, USA. ¹⁶ Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA, USA. 36 ¹⁷ Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA. 37 ¹⁸ Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA 38 ¹⁹ Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, VA Connecticut 39 40 Healthcare System, West Haven, CT, USA ²⁰ Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New 41 York, NY 10029, USA 42 43 44 45 46

48 49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Abstract Despite experiencing a significant trauma, only a subset of World Trade Center (WTC) rescue and recovery workers developed posttraumatic stress disorder (PTSD). Identification of biomarkers is critical to the development of targeted interventions for treating disaster responders and potentially preventing the development of PTSD in this population. Analysis of gene expression from these individuals can help in identifying biomarkers of PTSD. We established a well-phenotyped sample of 371 WTC responders, recruited from a longitudinal WTC responder cohort, by obtaining blood, self-reported and clinical interview data. Using bulk RNA-sequencing from whole blood, we examined the association between gene expression and WTC-related PTSD symptom severity on (i) highest lifetime Clinician-Administered PTSD Scale (CAPS) score, (ii) past-month CAPS score, and (iii) PTSD symptom dimensions using a 5factor model of re-experiencing, avoidance, emotional numbing, dysphoric arousal and anxious arousal symptoms. We corrected for sex, age, genotype-derived principal components and surrogate variables. Finally, we performed a meta-analysis with existing PTSD studies (total N=1,016), using case/control status as the predictor and correcting for these variables. We identified 66 genes significantly associated with highest lifetime CAPS score (FDRcorrected p<0.05), and 31 genes associated with past-month CAPS. Our more granular analyses of PTSD symptom dimensions identified additional genes that did not reach statistical significance in our overall analysis. In particular, we identified 82 genes significantly associated with lifetime anxious arousal symptoms. Several genes significantly associated with multiple PTSD symptom dimensions and lifetime CAPS score (SERPINA1, RPS6KA1, and STAT3) have

been previously associated with PTSD. Geneset enrichment of these findings has identified pathways significant in metabolism, immune signaling, other psychiatric disorders, neurological signaling, and cellular structure. Our meta-analysis revealed 10 genes that reached genome-wide significance, all of which were down-regulated in cases compared to controls (*CIRBP*, *TMSB10*, *FCGRT*, *CLIC1*, *RPS6KB2*, *HNRNPUL1*, *ALDOA*, *NACA*, *ZNF429* and *COPE*). Additionally, cellular deconvolution highlighted an enrichment in CD4 T cells and eosinophils in responders with PTSD compared to controls.

The distinction in significant genes between lifetime CAPS score and the anxious arousal symptom dimension of PTSD highlights a potential biological difference in the mechanism underlying the heterogeneity of the PTSD phenotype. Future studies should be clear about methods used to analyze PTSD status, as phenotypes based on PTSD symptom dimensions may yield different gene sets than combined CAPS score analysis. Potential biomarkers implicated from our meta-analysis may help improve therapeutic target development for PTSD.

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

Introduction Posttraumatic stress disorder (PTSD) is a complex psychiatric disorder that can develop after experiencing a traumatic event. The attacks on the World Trade Center (WTC) on September 11, 2001 and their aftermath had a substantial impact on the physical and mental health of WTC rescue, recovery and clean-up workers, but only a subset developed PTSD. These differing clinical outcomes after experiencing trauma imply a role for biological and genetic influence in PTSD. Our cohort provides an unprecedented opportunity into PTSD insights, because they have been deeply phenotyped for a shared, specific trauma. Understanding the biological mechanisms underlying PTSD will require careful dissection and analysis of many constituent symptoms and risk factors. PTSD is uniquely heterogeneous among psychiatric disorders, with complex and detailed diagnostic criteria that allow for 636,120 different combinations of symptoms¹, and 79,794 different symptom combinations. Additional heterogeneity in PTSD stems from the type and extent of trauma. It has been well established that PTSD is a heterogenous disorder and that trauma type plays a role in differential outcomes. In the field of WTC exposures, some work has already been done to elucidate gene expression and clinical outcomes. ^{2–10} Further, work by our group and others has demonstrated differential genetic heritability of PTSD according to trauma-type ^{11,12}. Identification of biomarkers will be critical to the development of targeted interventions for treating disaster responders and potentially preventing the development of PTSD in this population. Gene expression analysis from WTC responders is uniquely useful to deduce the biological heterogeneity in PTSD, given their exposure to a similar and well-documented trauma.

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Data on WTC-related traumatic exposures of responders analyzed here, in combination with their heterogenic clinical outcomes, makes this a critical study to understand PTSD development and chronicity after shared traumatic events. Although candidate gene expression and methylation studies have explored genes involved in canonical stress signaling pathways in PTSD, regulated by the hypothalamus-pituitary-adrenal (HPA) axis, and immune and sympathetic nervous systems, few have been able to control for length of time since exposure, nor so specifically delineate trauma type and secondary exposures such as dust cloud severity. While the WTC-related exposures experienced by rescue, recovery and clean-up workers in this cohort ranged in severity, the traumatic event –encompassing the 9/11 attacks and their aftermath– happened in a discrete, specific time window. Further, this sample is highly phenotyped with in-person clinical psychiatric evaluations, also including medical examination and laboratory testing. The existence of this cohort and the generous participation of many responders to the WTC disaster enabled us to generate a large gene expression data set of 355 donors, to our knowledge the largest single traumatic event expression data set to date. We used the Clinician-Administered PTSD Scale (CAPS)¹³ score as a quantitative measure of PTSD symptom severity rather than a case/control definition, thus substantially increasing statistical power in this study. 14-16 To our knowledge, ours is the first gene expression study to incorporate total CAPS scores and PTSD symptom dimensions as outcomes.

Methods

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Participants The WTC Health Program (WTC-HP) is a regional consortium of five clinical centers established in the greater New York City area by the Centers of Disease Control and Prevention in 2002, with the goal of providing health monitoring and treatment to WTC responders, comprising the WTC-HP General Responder Cohort¹⁷. We recruited participants from the WTC-HP Responder Cohort who had completed at least three periodic health monitoring visits at one of the four WTC-HP clinical centers participating in this study – Mount Sinai Medical Center, New York University, Northwell Health, and Rutgers/The State University of New Jersey – and who had provided signed consent to be contacted for research studies. Stratified random sampling was employed to ensure selection of WTC responders spanning the full range of WTCrelated PTSD symptom severity, from no/minimal symptoms to severe/chronic PTSD symptom levels on the PTSD Checklist – Specific Version (PCL-S)¹⁸ completed during periodic health monitoring visits to the WTC-HP. Individuals with a lifetime history of chronic psychotic disorder or bipolar disorder type I, substance abuse/dependence or alcohol dependence over the prior three months, current pregnancy, acute medical illness or exacerbation of chronic medical illness, history of significant head injury or cerebrovascular accident, changes in medications or medication dosages over the prior month, or who were taking oral or regularly injected steroid medications were excluded from the study. The study, conducted between April 2013 and September 2017, was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai, and all participants

provided written informed consent. A total of 471 WTC responders completed in-person clinical

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

assessments, yielding a final sample of 371 participants who met study eligibility criteria and completed study procedures, and 355 of those who had viable RNA-sequencing data (Figure 1). The mean age of participants was 54.1 (SD=8.3) years, 82% were male; ethnicity proportions are given in **Table 1**. The sample was composed of 40.8% police responders and 59.2% nontraditional responders (e.g., construction workers). **Assessments** Data on 10 WTC-related exposures ¹⁹(e.g., exposed to human remains, received treatment for an illness/injury during WTC recovery work) was obtained from interviews and self-report questionnaires completed by participants during their first health-monitoring visit to the WTC-HP, an average of 4.3 (SD=2.7) years following 9/11/2001. In-person clinical assessments were conducted an average of 13 (SD=2.3) years following 9/11/2011. Trained Masters- or PhD-level clinical interviewers administered the Structured Clinical Interview for DSM-IV (SCID)¹ to assess current and lifetime Axis-I psychiatric diagnoses, and CAPS¹³, lifetime and past-month versions, to assess lifetime and past-month WTC-related PTSD diagnostic status and WTCrelated PTSD symptom severity. Lifetime and past-month PTSD diagnosis was defined as meeting DSM-IV criteria for WTC-related PTSD and a total score ≥ 40 on the lifetime and pastmonth CAPS, respectively. On the same day as the clinical assessment, participants also completed the Childhood Trauma Questionnaire (CTQ)²⁰, assessing physical, sexual, and emotional abuse, and physical and emotional neglect experienced in childhood; the Traumatic Life Events Questionnaire (TLEQ)²¹, assessing lifetime exposure to a range of traumatic events (e.g., crime, natural disaster, assault); a

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

checklist of 15 stressful life events they might have experienced since 9/11/2011 (e.g., "lost a job/laid off/lost income", "divorced from spouse", "had debt trouble"), modified from the Diagnostic Interview Schedule (DIS) Disaster Supplement²²; and a health questionnaire asking which medical conditions they had ever been diagnosed with ²³, modified to add common WTCrelated conditions (asthma or chronic respiratory condition, chronic rhinitis or sinusitis, sleep apnea, or acid reflux). Participants additionally completed a history and physical examination conducted by a licensed nurse practitioner, as well as routine laboratory testing, to rule out acute medical illness or exacerbation of chronic medical illness. Among the 355 participants, 108 were determined to have met DSM-IV criteria for lifetime WTC-related PTSD, with 53 of them still meeting past-month PTSD criteria. The heterogeneity of PTSD confers some problems when attempting to analyze the disorder by case/control status alone. Case/control analyses do not fully capture the symptom complexity of the disorder, resulting in poor genomic modeling. Similarly, while overall PTSD symptom severity is a better quantitative measurement, it does not fully capture variability across PTSD symptomatology on a useful clinical level.²⁴ To address this variability, we examined five symptom dimensions (reexperiencing, avoidance, emotional numbing, dysphoric arousal and anxious arousal symptoms), assessed with the CAPS to more accurately examine the heterogeneity of PTSD symptomatology (Figure 2).²⁵ **Blood sample collection and RNA extraction** Participants were instructed to fast after midnight and underwent collection of blood samples

between 8:00 and 10:00 am. Total RNA was purified from whole blood collected in PAXgene

blood RNA tubes (Qiagen, Germantown, MD, USA) using a PAXgene blood RNA kit IVD (Qiagen, Germantown, MD, USA). Total RNA concentration and quality were estimated using a NanoDrop 200c spectrophotometer according to the manufacturer instructions (Thermo Fisher Scientific, Waltham, MA, USA). Samples with an optical density ratio 260/280 superior or equal to 1.8 passed the quality control. Total RNA concentration and quality were also estimated using an Agilent RNA 6000 nano kit and an Agilent 2100 bioanalyzer according to the manufacturer instructions (Agilent Technologies, Santa Clara, CA, USA). Samples with an RNA Integrity Number superior or equal to 7 passed the quality control. RNA samples (derived from blood) were processed for RNA Seq with polyA selection and sequenced on Illumina HiSeq High Output mode with a sequencing configuration of 2x150 paired-end reads (GENEWIZ, South Plainfield, NJ). A total of 10M paired reads per sample was set as a threshold to account for high globin reads; 29 samples were re-sequenced to meet threshold.

Gene expression quality control analysis

We processed whole-blood gene expression data using the RAPiD.19 RNA-sequencing pipeline, and calculated normalized TPM counts from RSEM.²⁶ We performed quality control analysis on the counts to verify sequencing and residual contributions to variance using VariancePartition²⁷. We corrected each sequencing batch for sex, age, and genotype-derived principal components using Limma/voom weighted least-squares linear regression.²⁸ We rank normalized and combined the residuals from the linear regression of each batch, and these values were used in all subsequent association tests for CAPS total score and five PTSD dimension scores (reexperiencing, avoidance, numbing, dysphoric arousal and anxious arousal).

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Differential gene expression analysis We used whole blood RNA-sequencing to test for associations between gene expression and WTC-related PTSD symptom severity on (i) highest lifetime CAPS score (CAPS_I), (ii) pastmonth CAPS score (CAPS_{PM}), and (iii) PTSD dimension scores including re-experiencing, avoidance, numbing, dysphoric arousal and anxious arousal, correcting for batch and surrogate variables (Eqn. 1). Gene expression $\sim Dx + batch + surrogate variables$ Equation 1. General equation for gene expression analysis. In addition, study participants had a wide range of psychiatric and somatic comorbidities, including some with substantial shared genetic aetiology and overlapping symptom profiles (e.g., major depressive disorder); comorbidities that may represent systemic manifestations of of PTSD (e.g., cardiovascular disease²⁹); and exposure to the dust cloud during and following 9/11. We expect all of these factors to have substantial impacts on gene expression. Significant colinearity between some of these measures and CAPS scores preclude including these variables as covariates within our analysis, and testing directly for their effect on gene expression (in particular, due to high correlations between length of time at the WTC site, CAPS score, and dust-cloud exposure [ref]; and between CAPS score and co-morbid medical disorders potentially constituting systemic manifestations of PTSD). Instead, in order to test whether these comorbidities and exposures might account for some of the CAPS-expression associations we observe, we also tested for gene expression associations with (i) an index of dust cloud

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

exposure³⁰; and (ii) number of medical comorbidities. Next, we tested for (i) interaction effects between each of these measures and CAPS score; (ii) enrichment of genome-wide significant associations between these measures and CAPS score; and (iii) genome-wide correlations in association statistics. For all gene expression analyses, we established significance using a Benjamini-Hochberg³¹ FDR correction < 5%. Gene-set enrichment of PTSD-associated genes We tested for gene set enrichment among our genes associated with CAPS_L, CAPS_{PM}, and PTSD dimension scores by (i) analyzing the significant genes from the association tests for pathway enrichment by gene permutation testing and (ii) analyzing all genes from the ranked association test gene lists to subject permutation using the R versions of GSEA³² and fgsea^{33,34}. For gene permutation testing, we included all nominally significant genes (p<0.05), and tested for association with 105 gene sets using Kyoto Encyclopedia of Genes and Genomes (KEGG) database³⁵ for pathway enrichment. We applied phenotype permutation testing rather than gene set permutation to keep the correlations between the genes in the dataset and the genes in the gene set pathways. For the subject permutation testing, each test was run with 10000 permutations, and pathways that passed Benjamini-Hochberg multiple testing correction were considered significantly enriched. To synthesize this large amount of gene set information, we generated comparative PTSD symptom plots using Clusterprofiler³⁶ in R. Comparative gene set plots contained pathways which passed FDR<0.05 significance threshold.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Meta-analysis with existing gene expression analyses To replicate our gene expression results, we meta-analyzed our data with association statistics from five other genome-wide gene expression analyses: 1. WTC responder study Stony Brook University (SB WTC) 3: N=282. Data are divided into discovery (WTC-d) and replication (WTC-r) cohorts. 2. Trauma Mega-Analysis study (TMA) 12. TMA combines 7 different PTSD studies and transformed the expression data into three categories: combat (N=169), male interpersonal (N=112), and female interpersonal trauma (N=259)¹². We analyzed these data as separate trauma studies for the purposes of our meta-analysis (Table 2). Since the majority of studies focus on PTSD case/control status, rather than associations with continuous CAPS scores (as here), we repeated our analysis to compare gene expression between PTSD cases (defined as meeting DSM-IV criteria for PTSD and a total CAPS \geq 40) and controls (all others in our sample). We meta-analyzed PTSD case-control association statistics using a sample-size based metaanalysis approach in METAL³⁷. We included all genes from our analysis that reached p<0.05 (N=9,380 for past-month and N=1,016 for lifetime) and all available genes from other studies (N=27-806; Table 2). Cellular deconvolution associated with CAPS scores We applied CIBERSORT to our raw counts matrix to deconvolute immune cell types in our patients using the immune cell matrix reference panel LM22³⁸. We tested for association between cell type proportions and CAPS_{PM} CAPS_L.

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Results Gene expression is associated with PTSD symptom levels in WTC first responders We tested for association between expression of 12,220 genes and total CAPS score in a sample of 355 WTC first responders. We identified 31 genes significantly associated with total pastmonth CAPS score (CAPS_{PM}; Figure 3), and 66 genes associated with lifetime (highest) CAPS score (CAPS_L, Figure 3). Of these, 42/66 genes are associated only with CAPS_L, (and not CAPS_{PM}), while 7/31 genes were associated only with CAPS_{PM}, (and not CAPS_L). Genome-wide associations with CAPS_{PM} and CAPS_L were significantly correlated (Beta $\rho = 0.82$, p<2.2x10⁻¹⁶; FDR-adjusted P-values $\rho = 0.79$, p<2.2x10⁻¹⁶) (Table 3). We tested for enrichment of 59 well-studied PTSD candidate genes¹¹ (Sup. Table 1) within our association statistics. We did not observe enrichment of these genes within our past-month or lifetime association analyses (p=0.174, 0.245). However, of these candidate genes, SERPINA1 was significantly associated with CAPS_L score. Environmental exposure to the WTC dust cloud Next, we tested whether our genes associated with CAPS scores are specific to PTSD, or are driven by spurious associations with comorbid diagnoses or environmental exposure to the dust cloud at Ground Zero. In particular, a number of individuals within our study have comorbid conditions and complex medical histories (Table 4), including disorders with substantial shared genetic and environmental etiology with PTSD, and disorders and traits that may present as systemic manifestations of PTSD.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

First, we tested whether these medical comorbidities alone may account for the associations we observe; we identified 175 gene associations with an aggregate summary score of medical comorbidities. Notably, these genes do not include any of our significant associations with CAPS scores. We identified only one gene, STX10, with significant interaction between CAPS scores and comorbid conditions; that is, gene expression was elevated specifically among individuals with both high CAPS_L and a large number of comorbid diagnoses (Figure 4). Next, we tested for association between gene expression and exposure to the dust cloud at Ground Zero³⁰. We identified 561 genes significantly associated with this exposure. We tested for, but did not find, any significant interactions between CAPS scores and dust cloud exposure (p>0.05), and did not observe a large correlation of expression results in genome-wide significant genes between the two analyses for CAPS_{PM} or CAPS_L (R²=0.1835, R²=0.2466, p<0.05) (Figure 4). Together, these analyses imply that our gene-CAPS score associations are specific and relevant to PTSD, rather than due to confounding by comorbid diagnoses or dust cloud exposure. Gene expression analysis reveals PTSD dimension-specific associations Next, we tested for gene expression associations with past-month and lifetime PTSD symptom dimensions (re-experiencing, avoidance, dysphoric arousal, anxious arousal, numbing; Sup. Table 2). Our analysis revealed overlapping and unique genes for each symptom dimension, and significant correlation of genome-wide association statistics between symptom dimensions.

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

In particular, both our past-month and lifetime analyses identified a large number of genes (61) and 82, respectively; Sup. Table 2) associated with anxious arousal, including many genes not associated with any other phenotype in our analysis (16, 27, respectively). By contrast, although we identified a substantial number of genes significantly associated with dysphoric arousal (20, 16 for past-month and lifetime respectively), only two genes were uniquely associated with this phenotype (1 gene in past-month; 2 in lifetime). Only one gene, *COPE*, was significantly associated with every phenotype tested in our analysis. A second gene, EIF4A1, was also significantly associated with every lifetime (highest) phenotype (Figure 5). PTSD pathway enrichment demonstrates immune, psychiatric, and metabolic relationships Our genetic enrichment and pathway analyses identified well-established PTSD mechanisms and pathways, including pathways associated with inflammation, neurological signaling pathways, structural remodeling within and between cells, and HPA-axis and signaling ^{39–44}. Based on our KEGG pathway enrichment analysis, we revealed a set of genes significantly associated with psychiatric disorders pathways that were significantly enriched in our results: FURIN, PPP2R1A, GNAI2, PCLB2, and GNB2. The two symptoms that we discovered were associated with FURIN and their FDR-corrected p-values were avoidance (p=0.028, B=2.55) and numbing (p=0.034, B=-0.009). PPP2R1A was associated with anxious arousal (p=0.009, B=2.60). PCLB2 was only associated with numbing (p=0.046, B=-0.952). GNAI2 was associated with anxious arousal (p=0.042, B=-0.780) and numbing (p=0.047, B=-1.03), and GNB2 was only associated with avoidance (p=0.036, B=1.130) (Figure 6).

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Immunological and metabolic gene enrichment was consistent across CAPS_L score and numbing, but was less pronounced in anxious arousal. For past-month analyses, immune function was most associated with anxious arousal, whereas metabolic function was enriched in CAPS_{PM} and numbing, to a lesser extent. For both lifetime and past-month scores, neurological signaling pathways were most significantly pronounced in numbing, and were less prevalent in the overall total CAPS score analysis. For lifetime scores, structural pathway enrichment was significantly higher in total CAPS score, anxious arousal, and numbing, whereas for past-month scores, structural enrichment was most associated with anxious arousal (Figure 6). Meta-analysis prioritizes 10 genes associated with PTSD We sought to replicate our associations with previous PTSD studies. Since the majority of publicly available PTSD gene expression analyses follow a case-control, rather than quantitative measure (CAPS score) analysis, we converted our continuous CAPS_{PM} and CAPS_L values to PTSD case/control using (CAPS≥ 40) and DSM-IV PTSD-criteria, and repeated our analysis. Our case/control and CAPS score association statistics were significantly correlated (ρ =0.72, $p<2.2x10^{-16}$, $\rho=0.79$, $p<2.2x10^{-16}$); however, we note a substantial decrease in the number of significantly associated genes when using a case-control design, compared to our initial quantitative analysis, as we would expect¹⁶. Twelve genes were significant for past-month PTSD (PTSD_{PM}) case/control and 22 genes were significant for lifetime PTSD (PTSD_L) case/control, versus 31 genes for CAPS_{PM} and 66 genes for CAPS_L. We meta-analyzed our results with five publicly available cohorts (N=739 cases, 438 controls); two including WTC responders, and three including combat and interpersonal trauma (Table 2).

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

For PTSD_{PM} we identified 5 significant genes –*COPE*, *CIRBP*, *FCGRT*, *NACA*, and *ZNF429* (p<5.33x10⁻⁶)–, and for PTSD_L 8 significant genes –*COPE*, *CIRBP*, *TMSB10*, *FCGRT*, *CLIC1*, RPS6KB2, HNRNPUL1 and ALDOA (p<4.92x10⁻⁵)—, including genes associated with inflammation and immune response (Figure 7). Of these 10 genes, only one (COPE) had significant heterogeneity of effect size between cohorts: our study and TMA-combat. Three further genes were unique to our study; NACA p=3.34x10⁻⁶, CLIC1, p=1.9x10⁻⁵, and HNRNPUL1 p=4.08 x10⁻⁵ (Figure 7). The remaining six genes were significant across multiple studies in our meta-analysis, with highly consistent (negative) direction of effect (i.e., consistently decreased expression in cases compared to controls): ZNF439 (p=4.78x10⁻⁶), CIRBP (p=1.29 x10⁻⁶), TMSB10 (p=6.31 x10⁻⁶), FCGRT (p=1.12 x10⁻⁵), RPS6KB2 (p=3.47 x10⁻⁵), and ALDOA (p=4.66) $x10^{-5}$) (Table 5). Cellular deconvolution identifies differences in cell populations between responders with **PTSD** and controls Since many of our PTSD-associated genes are related to immune function, we tested whether immune cell type proportions were correlated with CAPS scores in individuals in our sample. We performed cell-type deconvolution to identify cell-type proportions for 22 cell types across all 355 individuals in our sample. We found significant increase of CD4 naïve T cell (p<0.0049) proportions with CAPS_{PM}, and significant increase of eosinophils (p< 0.042) and CD4 memory resting T cells (p<0.044) associated with CAPS_L. In addition, we found significant decrease of activated natural killer cells (p<0.040) associated with CAPS_L (Figure 8).

Discussion

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

Although trauma is ubiquitous as a human experience, the types of traumatic experiences vary greatly among individuals. Our study sample and design present a unique opportunity to examine gene expression and PTSD symptoms related to a particular traumatic experience, the 9/11 WTC disaster and its aftermath. To our knowledge, ours is the largest single-traumatic event gene expression dataset to date. Using CAPS score as a quantitative measure of WTC-related PTSD symptom severity, we found 66 genes associated with lifetime (highest) CAPS score and 31 genes associated with past-month CAPS score. We additionally found interaction between CAPS_L and one gene, STX10, in medical comorbidities. Pathway analysis links our associated genes to metabolic, immunological, structural, and neurological pathways. In addition, we found 10 genes associated with lifetime and past-month PTSD: COPE, CIRBP, and FCGRT shared between the two; NACA and ZNF429 specific to past-month PTSD; and TMSB10, CLIC1, RPS6KB2, HNRNPUL1 and ALDOA specific to lifetime PTSD. Furthermore, cellular analysis of our cohort demonstrated an enrichment in CD4 T cells and eosinophils in responders with PTSD. Additionally, natural killer cells were decreased in these patients. Our findings support previous studies which tie together the immune system and PTSD as a systemic disease. Ultimately, these results represent an additional wealth of knowledge to help understand the genetic expression and biological etiology of PTSD and uncover potential biomarkers for the disease. Examining both lifetime and past-month CAPS scores allowed us to look at not only chronic effects of PTSD but longevity of the outcomes. While CAPS_{PM} is considered the standard for case/control analysis, looking at both CAPS_L and CAPS_{PM} allows us to ask more specific questions about the role and relevance of elevated gene expression in PTSD. For example, genes

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

associated with CAPS_{PM} might represent current expression changes in PTSD, while those associated with CAPS_I (lifetime CAPS score representing, for each responder, the highest WTCrelated PTSD symptom levels ever reached since 9/11/2011) may represent long-lasting expression changes resulting from lifetime PTSD. We identified genes associated with past-month and lifetime CAPS scores that have been associated with other psychiatric disorders, such as major depressive disorder, schizophrenia and autism: FURIN, PPP2R1A, PLCB2, GNAI2, and GNB2 (Figure 6)^{45–57}. We additionally identified a group of genes as significantly associated with several lifetime and past-month PTSD symptom dimensions (SERPINA1, RPS6KA1, and STAT3) that have been previously linked to PTSD pathophysiology 1,27-31, and genes associated specifically with anxious arousal that have been previously associated with anxiety disorders: *DCTN1*, and *FLI1*^{58,59}. One gene in our study, COPE, was associated with every PTSD phenotype in this analysis. Until now, COPE has not been well studied in the context of psychiatric disorders⁶⁰, but it has been implicated in the context of Alzheimer's disease 61,62. Canonically, the COPE protein is the epsilon subunit of the coatomer protein complex I (COPI) which regulates endocytosis from the plasma membrane and is involved in Golgi-to-lysosome transportation. Other subunits of COPI have been implicated in hereditary diseases that cause microcephaly and in autoimmune disorders^{63–65}. Importantly, our analytical design allowed us to test for potential confounding effects of comorbidities and environmental exposures^{66,67}. We expected many of these comorbidities and exposures to have a significant impact on gene expression, particularly as some comorbidities may be more recently occurring than, for example, the highest CAPS_L measure. Therefore, we

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

tested directly for genes associated with (i) comorbidities and (ii) dust cloud exposure. Although we identified a large number of genes associated with each phenotype, we note that our associations do not overlap with our top PTSD genes; we did not observe significant enrichment of shared associations, and only observed one gene with significant interaction effect between comorbidities and CAPS_L. Therefore, we conclude that our results are not confounded by these exposures; our gene associations are specific to PTSD rather than broadly corresponding to exposure or general ill-health. KEGG enrichment of our associated genes determined genetic changes in metabolic, immunological, structural, and neurological pathways associated with total CAPS, numbing, and anxious arousal phenotypes (Figure 7). Anxious arousal and numbing tend to have few significantly associated genes in common, while both past-month and lifetime CAPS scores display a few unique genes but many shared ones. GNAI2, while associated with many numbingrelated pathways (long-term depression, oxytocin signaling, etc.), is also significantly associated with some peripheral anxious arousal-related and CAPS_L-related pathways (leukocyte migration, and chemokine signaling, respectively). On the other hand, anxious arousal is uniquely associated with genes such as HGS, ARFGAP2 and RAB7A, which are linked to endocytosis and immunity. Similarly, our past-month and lifetime CAPS phenotypes are uniquely associated with glycolysis/gluconeogenesis for genes ALDOA, GAPDH, ENO1, TPI1, and PKM, which may play roles in HPA-axis or metabolic dysregulation (Table 4). Our analyses identified 10 genes reaching genome-wide significance. Of these, 3/10 (NACA) $p=3.34\times10^{-6}$, CLIC1, $p=1.9\times10^{-5}$, and HNRNPUL1 $p=4.08\times10^{-5}$) are specific to our study; all

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

three are downregulated in WTC responders with PTSD compared to controls. NACA has been previously studied as a potential biomarker for depression in mice under stress conditions⁶⁸. The function of *HNRNPUL1* is relatively unknown. Studies have suggested it might play a role in DNA damage repair and nucleocytoplasmic RNA transport. CLIC1 has been implicated in other psychiatric disorders, but its primary function is inflammasome regulation ^{69–71}. In addition, 6/10 genes had highly consistent directions of effect. These include FCGRT (p=1.12x⁻⁰⁵), which has been characterized as an immune regulator of dendritic cell cross-presentation of IgG immune complexes, necessary to activate a cytotoxic T-cell response and clear antigens⁷². Our analysis demonstrates a down-regulation of FCGRT in WTC responders with PTSD, suggesting reduced IgG immune complex clearance in these patients (Figure 6). There is evidence that macro- and micro-level physiological damage is a fundamental component of PTSD, as well as cytoskeletal restructuring for fear-based memory formation in the amygdala^{43,44}. In this study we observed decreased expression in *CIRBP* (p= 1.29x⁻⁰⁶), a protein that traditionally regulates stress and apoptosis under conditions of extreme cold (Figure 6). Its role as a potential biomarker has been previously explored for different psychiatric disorders 73,74. The decrease observed in *TMSB10* expression also contributes to the dysregulation of apoptosis. TMSB10 is a pro-apoptotic protein that has been previously associated with downregulation of gene expression after trauma exposure^{3,75,76}. In our meta-analysis, the directionality of effect $(p<2.2x^{-16})$ for each gene was decreased, consistent with PTSD pathophysiology^{77,78}. Since many of our PTSD-associated genes are related to immune function, we tested for the enrichment of immune cell types in our study. We found an overall enrichment of CD4-positive

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

T cells for both past-month and lifetime CAPS scores (Figure 7), consistent with previous studies^{79,80}, including among WTC responders⁸. In addition to CD4 T cell enrichment, our study also found enrichment in eosinophils and a decrease in natural killer cells for CAPS_L (Figure 7). These cellular diversities may point to a higher inflammatory signature in PTSD, particularly in the case of CD4 T cell enrichment. It has been well demonstrated that dysregulation of CD4 T cells leads to autoimmune activation⁸¹, and in combination with an increase in eosinophils can lead to an inflammatory cascade in patients. There is strong evidence that PTSD is associated with a pro-inflammatory state, which our findings support^{82–86}. While our study provides an in-depth look at the genetic expression and outcomes related to a specific traumatic experience, we note some significant caveats. Our expression analysis was limited to blood, but should be expanded to other tissues in the future, such as the brain. Similarly, our analysis was restricted to whole blood, but a more in-depth single cell analysis will be critical to determine gene expression in individual cell types. In addition, we note that our cohort includes a significant proportion of individuals who have self-selected into high-risk professions. As such, we expect a higher lifetime exposure to stressful situations, including potentially many other life-threatening scenarios. It is likely that the PTSD symptoms observed here are at least partially accounted for by other traumas and stressors, even though upon CAPS administration, study clinicians specifically inquired about WTC-related PTSD symptoms. Conversely, the high-risk nature of these individuals' occupations may also mean increased exposure to resilience training for a sizable subsample, and greater access to social support networks of peers with similar experiences, potentially providing protective mechanisms.

In conclusion, this study has identified a vast number of biomarkers that will be potentially useful tools after independent validation. In particular, ten of these genes stand out as reproducible across multiple studies and should be considered as high priority. In combination with pathway and cellular deconvolution results, these findings highlight a strong connection with immune dysregulation and other psychiatric illnesses. We believe that future studies should focus on validation of our PTSD-associated genes and also single-cell RNA-sequencing approaches to delineate the role of immune cell types in PTSD.

References

524

- 1. Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I
- 526 Disorders (SCID). N. Y. State Psychiatr. Inst. Biom. Res. N. Y. (1995).
- 527 2. Yehuda, R. et al. Gene Expression Patterns Associated with Posttraumatic Stress Disorder
- Following Exposure to the World Trade Center Attacks. *Biol. Psychiatry* **66**, 708–711 (2009).
- 529 3. Kuan, P.-F. et al. Gene expression associated with PTSD in World Trade Center responders:
- An RNA sequencing study. *Transl. Psychiatry* 7, 1297 (2017).
- 4. Clouston, S. et al. Traumatic exposures, posttraumatic stress disorder, and cognitive
- functioning in World Trade Center responders. *Alzheimers Dement. N. Y. N* **3**, 593–602
- 533 (2017).
- 534 5. Clouston, S. A. P. et al. Posttraumatic stress disorder and total amyloid burden and amyloid-
- β 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders.
- 536 Alzheimers Dement. Amst. Neth. **11**, 216–220 (2019).
- 6. Clouston, S. A. P. et al. Incidence of mild cognitive impairment in World Trade Center
- responders: Long-term consequences of re-experiencing the events on 9/11/2001.
- 539 *Alzheimers Dement. Diagn. Assess. Dis. Monit.* **11**, 628–636 (2019).
- 7. Gong, Y. et al. Prostate Cancer in World Trade Center Responders Demonstrates Evidence
- of an Inflammatory Cascade. *Mol. Cancer Res.* **17**, 1605–1612 (2019).
- 8. Kuan, P.-F. et al. Cell type-specific gene expression patterns associated with posttraumatic
- stress disorder in World Trade Center responders. *Transl. Psychiatry* **9**, 1–11 (2019).
- 544 9. Kuan, P.-F. et al. Enhanced exposure assessment and genome-wide DNA methylation in
- World Trade Center disaster responders. Eur. J. Cancer Prev. 28, 225–233 (2019).

- 10. Sarapas, C. et al. Genetic Markers for PTSD Risk and Resilience Among Survivors of the
- World Trade Center Attacks. Dis. Markers 30, 101–110 (2011).
- 11. Huckins, L. M. et al. Analysis of Genetically Regulated Gene Expression identifies a trauma
- type specific PTSD gene, SNRNP35. bioRxiv 581124 (2019) doi:10.1101/581124.
- 12. Breen, M. S. et al. PTSD Blood Transcriptome Mega-Analysis: Shared Inflammatory
- Pathways across Biological Sex and Modes of Trauma. *Neuropsychopharmacology* **43**, 469–
- 552 481 (2018).
- 13. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD
- 554 Scale. J Trauma Stress 8(1), 75–90 (1995).
- 14. Fanous, A. H. & Kendler, K. S. Genetic heterogeneity, modifier genes, and quantitative
- phenotypes in psychiatric illness: searching for a framework. *Mol. Psychiatry* **10**, 6–13
- 557 (2005).
- 15. Schijven, D. et al. Multivariate genome-wide analysis of stress-related quantitative
- phenotypes. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 29, 1354–
- 560 1364 (2019).
- 16. Lee, S. H. & Wray, N. R. Novel Genetic Analysis for Case-Control Genome-Wide Association
- Studies: Quantification of Power and Genomic Prediction Accuracy. *PLoS ONE* **8**, (2013).
- 17. Dasaro, C. R. et al. Cohort Profile: World Trade Center Health Program General Responder
- 564 Cohort. *Int. J. Epidemiol.* **46**, e9 (2017).
- 18. Ruggiero, K. J., Del Ben, K., Scotti, J. R. & Rabalais, A. E. Psychometric properties of the PTSD
- 566 Checklist-Civilian Version. J. Trauma. Stress 16, 495–502 (2003).

- 19. Huckins, L. M. et al. Polygenic regulation of PTSD severity and outcomes among World
- Trade Center responders. *medRxiv* 2020.12.06.20244772 (2020)
- 569 doi:10.1101/2020.12.06.20244772.
- 570 20. Bernstein, D. P. et al. Development and validation of a brief screening version of the
- 571 Childhood Trauma Questionnaire. *Child Abuse Negl.* **27**, 169–190 (2003).
- 572 21. Kubany, E. S. et al. Development and preliminary validation of a brief broad-spectrum
- measure of trauma exposure: the Traumatic Life Events Questionnaire. Psychol. Assess. 12,
- 574 210–224 (2000).
- 575 22. North, CS., et al. The Diagnostic Interview Schedule/Disaster Supplement (DIS-IV/DS). St
- 576 *Louis Wash. Univ.* (2001).
- 577 23. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Medical comorbidity of full
- and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National
- 579 Epidemiologic Survey on Alcohol and Related Conditions. *Psychosom. Med.* **73**, 697–707
- 580 (2011).
- 581 24. Horn, S. R. et al. Latent typologies of posttraumatic stress disorder in World Trade Center
- responders. *J. Psychiatr. Res.* **83**, 151–159 (2016).
- 583 25. Pietrzak, R. H., Tsai, J., Harpaz-Rotem, I., Whealin, J. M. & Southwick, S. M. Support for a
- novel five-factor model of posttraumatic stress symptoms in three independent samples of
- Iraq/Afghanistan veterans: a confirmatory factor analytic study. J. Psychiatr. Res. 46, 317–
- 586 322 (2012).
- 587 26. Shah, H., Wang, Y.-C., Castellanos, R., Pandya, C., & Giles, Z. RAPiD An Agile and
- Dependable RNA-Seg Framework. ASHG 2015 (2015).

- 589 27. Hoffman, G. E. & Schadt, E. E. variance Partition: interpreting drivers of variation in complex
- gene expression studies. *BMC Bioinformatics* **17**, 483 (2016).
- 591 28. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model
- analysis tools for RNA-seg read counts. *Genome Biol.* **15**, R29 (2014).
- 593 29. Mellon, S. H., Gautam, A., Hammamieh, R., Jett, M. & Wolkowitz, O. M. Metabolism,
- Metabolomics, and Inflammation in Posttraumatic Stress Disorder. Biol. Psychiatry 83, 866–
- 595 875 (2018).
- 596 30. Wisnivesky, J. P. et al. Persistence of multiple illnesses in World Trade Center rescue and
- recovery workers: a cohort study. Lancet Lond. Engl. 378, 888–897 (2011).
- 598 31. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful
- Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
- 600 32. Bild, A. & Febbo, P. G. Application of a priori established gene sets to discover biologically
- 601 important differential expression in microarray data. *Proc. Natl. Acad. Sci.* **102**, 15278–
- 602 15279 (2005).
- 603 33. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. bioRxiv
- 604 060012 (2019) doi:10.1101/060012.
- 605 34. How to do GSEA in R with (fgsea or gage) and plot results. Bioinformatics Breakdown
- https://bioinformaticsbreakdown.com/how-to-gsea/ (2019).
- 35. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference
- resource for gene and protein annotation. *Nucleic Acids Res.* **44**, D457–D462 (2016).
- 36. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for Comparing
- Biological Themes Among Gene Clusters. *OMICS J. Integr. Biol.* **16**, 284–287 (2012).

- 37. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
- association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 38. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles.
- 614 *Nat. Methods* **12**, 453–457 (2015).
- 615 39. Daskalakis, N. P., Rijal, C. M., King, C., Huckins, L. M. & Ressler, K. J. Recent Genetics and
- Epigenetics Approaches to PTSD. Curr. Psychiatry Rep. 20, 30 (2018).
- 40. Neigh, G. N. & Ali, F. F. Co-Morbidity of PTSD and Immune System Dysfunction:
- 618 Opportunities for Treatment. Curr. Opin. Pharmacol. 29, 104–110 (2016).
- 41. Wang, Z., Caughron, B. & Young, M. R. I. Posttraumatic Stress Disorder: An Immunological
- 620 Disorder? Front. Psychiatry 8, (2017).
- 42. Speer, K. E., Semple, S., Naumovski, N., D'Cunha, N. M. & McKune, A. J. HPA axis function
- and diurnal cortisol in post-traumatic stress disorder: A systematic review. *Neurobiol. Stress*
- 623 **11**, (2019).
- 43. Yehuda, R. et al. Post-traumatic stress disorder. Nat. Rev. Dis. Primer 1, 1–22 (2015).
- 44. Nutt, D. J. & Malizia, A. L. Structural and functional brain changes in posttraumatic stress
- 626 disorder. J. Clin. Psychiatry **65 Suppl 1**, 11–17 (2004).
- 45. Duncan, L. E. et al. Largest GWAS of PTSD (N=200070) yields genetic overlap with
- schizophrenia and sex differences in heritability. *Mol. Psychiatry* **23**, 666–673 (2018).
- 629 46. Li, Z. et al. Genome-wide association analysis identifies 30 new susceptibility loci for
- 630 schizophrenia. *Nat. Genet.* **49**, 1576–1583 (2017).
- 631 47. Jong, S. de et al. Immune signatures and disorder-specific patterns in a cross-disorder gene
- expression analysis. *Br. J. Psychiatry* **209**, 202–208 (2016).

- 48. Tsolakidou, A. et al. Gene expression profiling in the stress control brain region
- hypothalamic paraventricular nucleus reveals a novel gene network including Amyloid beta
- Precursor Protein. *BMC Genomics* **11**, 546 (2010).
- 636 49. Maccarrone, G. et al. Psychiatric patient stratification using biosignatures based on
- 637 cerebrospinal fluid protein expression clusters. J. Psychiatr. Res. 47, 1572–1580 (2013).
- 638 50. Hou, Y. et al. Schizophrenia-associated rs4702 G allele-specific downregulation of FURIN
- expression by miR-338-3p reduces BDNF production. Schizophr. Res. 199, 176–180 (2018).
- 51. Schrode, N. et al. Synergistic effects of common schizophrenia risk variants. Nat. Genet. 51,
- 641 1475-1485 (2019).
- 52. English, J. A. *et al.* Reduced protein synthesis in schizophrenia patient-derived olfactory
- 643 cells. *Transl. Psychiatry* **5**, e663–e663 (2015).
- 53. Miron, J. et al. Association of PPP2R1A with Alzheimer's disease and specific cognitive
- domains. *Neurobiol. Aging* **81**, 234–243 (2019).
- 54. Bralten, J. et al. Candidate Genetic Pathways for Attention-Deficit/Hyperactivity Disorder
- 647 (ADHD) Show Association to Hyperactive/Impulsive Symptoms in Children With ADHD. J.
- 648 Am. Acad. Child Adolesc. Psychiatry **52**, 1204-1212.e1 (2013).
- 55. Chang, W.-S., Wang, Y.-H., Zhu, X.-T. & Wu, C.-J. Genome-Wide Profiling of miRNA and
- mRNA Expression in Alzheimer's Disease. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 23,
- 651 2721–2731 (2017).
- 652 56. Kawai, T. *et al.* Gene expression signature in peripheral blood cells from medical students
- exposed to chronic psychological stress. *Biol. Psychol.* **76**, 147–155 (2007).

- 654 57. Zhao, Y. et al. A large-scale integrative analysis of GWAS and common meQTLs across whole
- life course identifies genes, pathways and tissue/cell types for three major psychiatric
- disorders. *Neurosci. Biobehav. Rev.* **95**, 347–352 (2018).
- 657 58. Konno, T. et al. DCTN1-related neurodegeneration: Perry syndrome and beyond.
- 658 *Parkinsonism Relat. Disord.* **41**, 14–24 (2017).
- 59. Seth, A., Giunta, S., Franceschil, C., Kola, I. & Venanzoni, M. C. Regulation of the human
- stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. Cell Death
- 661 *Differ.* **6**, 902–907 (1999).
- 662 60. St-Louis, É. et al. Involvement of the coatomer protein complex I in the intracellular traffic
- of the delta opioid receptor. Mol. Cell. Neurosci. 79, 53–63 (2017).
- 664 61. Bettayeb, K. et al. Relevance of the COPI complex for Alzheimer's disease progression in
- 665 vivo. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 5418–5423 (2016).
- 666 62. Yang, Y., Wang, X., Ju, W., Sun, L. & Zhang, H. Genetic and Expression Analysis of COPI
- 667 Genes and Alzheimer's Disease Susceptibility. Front. Genet. 10, 866 (2019).
- 668 63. Izumi, K. et al. ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-
- 669 Mediated Transport Defects. Am. J. Hum. Genet. 99, 451–459 (2016).
- 670 64. Watkin, L. B. et al. COPA mutations impair ER-Golgi transport and cause hereditary
- autoimmune-mediated lung disease and arthritis. *Nat. Genet.* **47**, 654–660 (2015).
- 672 65. Jean, F., Stuart, A. & Tarailo-Graovac, M. Dissecting the Genetic and Etiological Causes of
- 673 Primary Microcephaly. *Front. Neurol.* **11**, (2020).

- 66. Lippmann, M., Cohen, M. D. & Chen, L.-C. Health effects of World Trade Center (WTC) Dust:
- An unprecedented disaster with inadequate risk management. Crit. Rev. Toxicol. 45, 492–
- 676 530 (2015).
- 677 67. Reibman, J. et al. Characteristics of a Residential and Working Community With Diverse
- 678 Exposure to World Trade Center Dust, Gas, and Fumes. J. Occup. Environ. Med. Am. Coll.
- 679 *Occup. Environ. Med.* **51**, 534–541 (2009).
- 680 68. Hervé, M. et al. Translational Identification of Transcriptional Signatures of Major
- 681 Depression and Antidepressant Response. Front. Mol. Neurosci. 10, (2017).
- 682 69. Carlini, V. et al. CLIC1 Protein Accumulates in Circulating Monocyte Membrane during
- Neurodegeneration. Int. J. Mol. Sci. 21, (2020).
- 70. Tang, T. et al. CLICs-dependent chloride efflux is an essential and proximal upstream event
- for NLRP3 inflammasome activation. *Nat. Commun.* **8**, 202 (2017).
- 71. Gurunathan, G., Yu, Z., Coulombe, Y., Masson, J.-Y. & Richard, S. Arginine methylation of
- 687 hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. Sci.
- 688 Rep. **5**, 10475 (2015).
- 689 72. Baker, K. et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG
- immune complexes by CD8-CD11b+ dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 108, 9927-
- 691 9932 (2011).
- 73. Le-Niculescu, H. et al. Towards precision medicine for stress disorders: diagnostic
- biomarkers and targeted drugs. *Mol. Psychiatry* **25**, 918–938 (2020).
- 74. Zhu, X., Bührer, C. & Wellmann, S. Cold-inducible proteins CIRP and RBM3, a unique couple
- 695 with activities far beyond the cold. *Cell. Mol. Life Sci.* **73**, 3839–3859 (2016).

- 696 75. Zhou, J.-Y. et al. Trauma-associated Human Neutrophil Alterations Revealed by Comparative
- 697 Proteomics Profiling. *Proteomics Clin. Appl.* **7**, (2013).
- 76. Lu, Q., Shen, N., Li, X. M. & Chen, S. L. Genomic view of IFN-α response in pre-autoimmune
- 699 NZB/W and MRL/lpr mice. *Genes Immun.* **8**, 590–603 (2007).
- 700 77. Chen, Y., Li, X., Kobayashi, I., Tsao, D. & Mellman, T. A. Expression and methylation in
- 701 posttraumatic stress disorder and resilience; evidence of a role for odorant receptors.
- 702 *Psychiatry Res.* **245**, 36–44 (2016).
- 78. Breen, M. S. et al. Differential transcriptional response following glucocorticoid activation in
- cultured blood immune cells: a novel approach to PTSD biomarker development. *Transl.*
- 705 *Psychiatry* **9**, 201 (2019).
- 706 79. Glover, D. A., Steele, A. C., Stuber, M. L. & Fahey, J. L. Preliminary evidence for lymphocyte
- distribution differences at rest and after acute psychological stress in PTSD-symptomatic
- 708 women. Brain. Behav. Immun. 19, 243–251 (2005).
- 709 80. Lemieux, A., Coe, C. L. & Carnes, M. Symptom severity predicts degree of T cell activation in
- adult women following childhood maltreatment. Brain. Behav. Immun. 22, 994–1003
- 711 (2008).
- 712 81. Skapenko, A., Leipe, J., Lipsky, P. E. & Schulze-Koops, H. The role of the T cell in autoimmune
- 713 inflammation. Arthritis Res. Ther. 7, S4–S14 (2005).
- 714 82. Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M. & Mondelli, V. Childhood trauma and
- adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and
- 716 tumour necrosis factor-α. *Mol. Psychiatry* **21**, 642–649 (2016).

83. Dong, Y. *et al.* Stress-induced NLRP3 inflammasome activation negatively regulates fear
memory in mice. *J. Neuroinflammation* 17, 205 (2020).
84. Fonkoue, I. T. *et al.* Symptom severity impacts sympathetic dysregulation and inflammation
in post-traumatic stress disorder (PTSD). *Brain. Behav. Immun.* 83, 260–269 (2020).
85. Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J. & Jovanovic, T. Inflammation in

Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. *Neuropsychopharmacology* **42**,

723 254–270 (2017).

725

726

86. Speer, K., Upton, D., Semple, S. & McKune, A. Systemic low-grade inflammation in post-

traumatic stress disorder: a systematic review. J. Inflamm. Res. 11, 111–121 (2018).

Table 1. Demographic and Other Characteristics

Table 1. Delliographic and Other Characteristics		
	Mean (SD) or N (%)	_
Age (years)	54.1 (8.3)	Mean (SD)
Number of years post-9/11 sample collected	13 (2.3)	Mean (SD)
BMI	30.1 (5.9)	Mean (SD)
Male sex	291 (82)	N (%)
Current smoker	22 (6.2)	N (%)
High school graduate	301 (84.9)	N (%)
Annual income > \$90,000	178 (50.1)	N (%)
Responder type		
Police responder	145 (40.8)	N (%)
Non-traditional responder	210 (59.2)	N (%)
Race-ethnicity		
African American	64 (18)	N (%)
Asian	5 <u>(</u> 1.4)	N (%)
Hispanic	72 (20.3)	N (%)
Native American	9 (2.5)	N (%)
European American (White)	216 (60.8)	N (%)
Other	8 (2.3)	N (%)

Note: SD = standard deviation; BMI= body mass index; n=355

medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21252989; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 2. Gene Expression Studies Included in Meta-Analysis

Trauma Study	ISMMS	WTC-d³	WTC-r³	TMA-C ¹²	TMA-MI ¹²	TMA-FI ¹²
Past-month PTSD/control, N subjects	53/302	57/138	24/63	N/A	N/A	N/A
Lifetime PTSD/Control, N subjects	108/247	N/A	N/A	85/84	45/67	99/160
Total N subjects	355	195	87	169	112	259
Available genes (p<0.05), N	1016	27	27	806	418	418
Age, Mean	54.1 (8.3)	52 (8.12)	52 (8.12)	24.4 (4.7)	41.1 (12.8)	39.5 (12.3)
Male, N (%)	291 (82)	195 (100)	87 (100)	169 (100)	112 (100)	0 (0)
European American, N (%)	216 (60.8)	165 (84.6)	74 (84.6)	108 (63.6)	34 (30.3)	62 (23.9)
African American, N (%)	64 (18)	N/A	N/A	N/A	78 (69.7)	197 (76.1)
Hispanic, N (%)	72 (20.3)	N/A	N/A	N/A	N/A	N/A

Note: ISMMS=Icahn School of Medicine at Mount Sinai (this study); WTC-d=Stony Brook World Trade Center discovery cohort; WTC-r=Stony Brook World Trade Center replication cohort; TMA-C=Trauma mega-analysis combat cohort; TMA-MI=Trauma mega-analysis male-interpersonal cohort; TMA-FI=Trauma mega-analysis female-interpersonal cohort. ³Kuan PF et al 2017, ¹²Breen MS et al 2018.

Table 3. Bivariate Correlations Between Lifetime and Past-month Total CAPS Scores and PTSD Symptom Dimensions

Lifetime vs. Past-month	R² (of beta values)	р	R ² (of FDR-adjusted P values)	р	
Total CAPS score	0.82	<2.2x10-16	0.79	<2.2x10-16	
Re-experiencing	0.66	<2.2x10-16	0.63	<2.2x10-16	
Anxious Arousal	0.8	<2.2x10-16	0.77	<2.2x10-16	
Avoidance	0.73	<2.2x10-16	0.71	<2.2x10-16	
Dysphoric Arousal	0.75	<2.2x10-16	0.72	<2.2x10-16	
Numbing	0.66	<2.2x10-16	0.64	<2.2x10-16	

Bivariate Correlations Between PTSD Symptom Dimensions

Past-month	Re-experiencing	Anxious Arousal	Avoidance	Dysphoric Arousal	Numbing
Re-experiencing	1	0.53	0.63	0.59	0.62
Anxious Arousal		1	0.57	0.64	0.55
Avoidance			1	0.61	0.63
Dysphoric Arousal				1	0.71
Numbing					1
Lifetime	Re-experiencing	Anxious Arousal	Avoidance	Dysphoric Arousal	Numbing
Lifetime Re-experiencing	Re-experiencing 1	Anxious Arousal 0.72	Avoidance 0.79	Dysphoric Arousal 0.75	Numbing 0.73
	Re-experiencing 1			, ,	
Re-experiencing	Re-experiencing 1		0.79	0.75	0.73
Re-experiencing Anxious Arousal	Re-experiencing 1		0.79	0.75 0.73	0.73 0.69

Note: CAPS = Clinician-Administered PTSD Scale; FDR = false discovery rate.

Table 4. Comorbid Medical Conditions

Table +1 Collidible Wiceles	Contaitions
Conditions	N (%)
Hypertension	162 (45.6)
Cardiac disease	28 (7.9)
Diabetes	44 (12.4)
GERD	184 (51.8)
Chronic pain	144 (40.6)
Arthritis	138 (38.9)
Asthma	161 (45.4)
Cancer	51 (14.4)
Chronic rhinitis	169 (47.6)
Sleep apnea	127 (35.8)
Kidney disease	8 (2.3)
Chronic skin condition	70 (19.7)
High cholesterol	174 (49)
Liver disease	15 (4.3)
Migraine	50 (14.1)
Osteoporosis	11 (3.1)
Rheumatoid Arthritis	15 (4.3)
Stroke	4 (1.1)
Traumatic brain injury	5 (1.4)

Note: GERD = gastroesophageal reflux disease.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21252989; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 5. Meta-analysis of Study Results With Five Publicly Available Cohorts Lifetime PTSD

					Heterogenous I-	Heterogenous	Heterogenous	Heterogenous	
Marker Name	Weight	Z-score	P-value	Direction	Squared	Chi-Squared	degrees of freedom	P value	
COPE	524	-5.277	1.31E-07	-??-??	91.7	12.103	1	0.0005034	
CIRBP	982	-4.842	1.29E-06	?	0	3.785	4	0.4358	
TMSB10	442	-4.516	6.31E-06	????	32	1.47	1	0.2253	
FCGRT	1177	-4.392	1.12E-05	+-	52	10.423	5	0.06411	
ALDOA	895	-4.072	4.66E-05	-??	43.2	5.281	3	0.1523	
RPS6KB2	1177	-4.14	3.47E-05	+	50.5	10.099	5	0.07248	
HNRNPUL1	355	-4.103	4.08E-05	-?????	0	0	0	1	
CLIC1	355	-4.276	1.90E-05	-?????	0	0	0	1	

Past-month PTSD

					Heterogenous I-	Heterogenous	Heterogenous	Heterogenous
Marker Name	Weight	Z-score	P-value	Direction	Squared	Chi-Squared	degrees of freedom	P value
COPE	524	-4.778	1.77E-06	-??-??	89.8	9.826	1	0.00172
CIRBP	982	-5.016	5.27E-07	?	0	3.676	4	0.4516
FCGRT	1177	-4.793	1.64E-06	+	59.9	12.475	5	0.02883
ZNF439	451	-4.574	4.78E-06	???	0	1.695	2	0.4285
NACA	355	-4.649	3.34E-06	-77777	0	0	0	1

Note: CAPS-5 = Clinician-Administered PTSD Scale. Direction is defined as our study, WTC discovery cohort³, WTC replication cohort³, military trauma, male interpersonal trauma and female interpersonal trauma (from mega-analysis study¹²). ³Kuan PF et al 2017, ¹²Breen MS et al 2018.


- Figure 1. Number of World Trade Center first respondents who completed the study with viable RNA-sequencing data, N=355.
- Figure 2. Distribution of lifetime and past-month severity scores for (A) CAPS, (B) numbing, (C) avoidance, (D) re-experiencing, (E) anxious arousal and (F) dysphoric arousal. PTSD symptom dimensions are scored from 0-50, and CAPS is an aggregate of that score. Total N=355 World Trade Center responders.
- Figure 3. **Differential gene expression analysis** of A) lifetime CAPS B) CAPS past-month C) anxious arousal lifetime and d) anxious arousal past-month in N=355 World Trade Center first-responders. Total number of differentially expressed genes (p<0.05): A) N=66, B) N=31, C) N=86, D) N=61. Phenotypes were corrected for sex, age, batch, and first 10 ancestry principal components.
- Figure 4. Dust cloud severity (A-B) and disease comorbidity (C-D) of CAPS lifetime and past-month genome-wide correlations. (E) Interaction term, *STX10*, of disease comorbidity and CAPS lifetime. SumMed: summary of medical terms for disease comorbidity; CAPS-LT: CAPS lifetime.
- Figure 5. **Heatmap of differentially expressed (p<0.05) genes** from a gene expression analysis across (A) past-month CAPS and symptom dimensions and (B) lifetime CAPS and symptom dimensions in N=355 World Trade Center first-responders. Phenotypes were corrected for sex, age, batch, and first 10 ancestry principal components. Gene clusters represent genealogical expression diversity among lifetime total CAPS and symptom dimensions.
- Figure 6. **KEGG pathway enrichment** of differentially expressed genes in N=355 World Trade Center first-responders in (A) past-month and (B) lifetime CAPS. Pathways categorically grouped by metabolic, immune signaling, innate immunity, structural, hormonal/neurological, regenerative and psychiatric function.
- Figure 7. Forestplots (A-E) and volcano plot (F) of genome-wide significant genes from our meta-analysis. Meta-analysis included our gene expression analysis, another World Trade Center (WTC) study, and a mega-analysis of 7 different compiled trauma studies.
- Figure 8. **Cellular deconvolution of immune cells in peripheral blood.** Significant cell type differences for CAPS lifetime and past-month compared to controls are noted.
- Table 1. Demographic information of N=355 World Trade Center first responders
- Table 2. Medical comorbidities and corresponding N of World Trade Center first responders with each comorbidity.
- Table 3. Significant (p<0.05) genes associated with each phenotype and corresponding statistical values: log2 fold change, average expression, t-statistic, p value, FDR-corrected p


value, and beta value. Phenotypes included are lifetime CAPS and past-month CAPS and all symptom dimensions.

Table 4. **PTSD** and demographic information of meta-analysis study. Includes Stony Brook World Trade Center cohort and a mega-analysis study split into combat, male interpersonal and female interpersonal trauma.

Table 5. **Table of genome-wide significant genes from our meta-analysis for lifetime and past-month PTSD.** Meta-analysis included our gene expression analysis, another World Trade Center (WTC) study, and a mega-analysis of 7 different compiled trauma studies. Direction is defined as our study, WTC discovery cohort, WTC replication cohort, military trauma, male interpersonal trauma and female interpersonal trauma (from the mega-analysis study).


Supplemental Table 2. (A) Correlations of beta values and FDR-adjusted p values for CAPS lifetime versus past-month and all associated symptom dimensions. (B) Correlations of symptom dimensions against all other symptom dimensions for past-month and (C) lifetime. All correlations were significant ($p<2.2x10^{-16}$).






A. Total Lifetime CAPS Score


B. Total Past-month CAPS Score






C. Lifetime Anxious Arousal

D. Past-month Anxious Arousal





A. Total Lifetime CAPS Score B. Total Past-month CAPS Score

